ProCE Banner Activity

JULIET: Phase II Primary Analysis of CAR T-Cell Therapy Tisagenlecleucel in Adult Patients With Relapsed/Refractory DLBCL

Slideset Download
Conference Coverage
Tisagenlecleucel (CTL019) demonstrated an ORR of 53% with most CRs sustained at 6 months in patients with hard-to-treat relapsed/refractory DLBCL.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology